Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+hematopoietic progenitor cells

• Verfasst von: Haas, Rainer [VerfasserIn]
• Verfasst von: Möhle, Robert [VerfasserIn]
• Verfasst von: Pförsich, Margit [VerfasserIn]
• Verfasst von: Frühauf, Stefan [VerfasserIn]
• Verfasst von: Witt, Barbara [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Hunstein, Werner [VerfasserIn]
• Titel: Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+hematopoietic progenitor cells
• Verf.angabe: Rainer Haas, Robert Möhle, Margit Pförsich, Stefan Fruehauf, Barbara Witt, Hartmut Goldschmidt, Werner Hunstein
• E-Jahr: 1995
• Jahr: 1 April 1995
• Umfang: 8 S.
• Fussnoten: Elektronische Reproduktion der Druck-Ausgabe 21. Dezember 2020 ; Im Titel ist "+" hochgestellt ; Gesehen am 19.05.2025
• Titel Quelle: Enthalten in: Blood
• Ort Quelle: Washington, DC : American Society of Hematology, 1946
• Jahr Quelle: 1995
• Band/Heft Quelle: 85(1995), 7, Seite 1936-1943
• ISSN Quelle: 1528-0020
• DOI: doi:10.1182/blood.V85.7.1936.bloodjournal8571936
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1926028791

Abstract

It was the objective of the study to characterize CD34+ hematopoietic progenitor cells from peripheral blood (PB) and bone marrow (BM) in a group of 24 cancer patients. After cytotoxic chemotherapy, R-metHu granulocyte colony-stimulating factor (R-metHuG-CSF; filgrastim, 300 μ g daily, subcutaneously) was given to shorten the time of neutropenia as well as to increase the rebound of peripheral blood progenitor cells (PBPC) for harvesting. The proportion of CD34+ cells in the leukapheresis products (LPs) was 1.4-fold greater than in BM samples that were obtained at the same day (LP: median, 1.4% vBM: median, 1.0%, P ≪ .01). Two- and three- color immunofluorescence showed that blood-derived CD34+ cells comprised a greater proportion of a particular early progenitor cell than CD34+ cells of bone marrow. Blood-derived progenitor cells tended to have a higher mean fluorescence intensity of CD34 and expressed significantly lower levels of HLA-DR (mean fluorescence intensity of HLA- DR: 442.6 B1 44.9 [LP] v 661.5 B1 64.6 [BM], mean B1 SEM, P ≪ .01). Furthermore, the blood-derived CD34+ cells comprised a 1.7-fold greater proportion of Thy-1+ cells (LP: median, 24.4% v BM: median, 14.4%, P ≪ .001) and expressed significantly less c-kit (LP: median, 20.5% v BM: median, 31.0%, P ≪ .01). Three-color analysis showed that high levels of Thy-1 expression were restricted to CD34+/HLA-DRdim or CD34+/HLA-DR− cells confirming the early developmental stage of this progenitor cell subset. The proportion of CD34+/CD45RAbright cells representing late colony-forming unit granulocyte-macrophage (CFU-GM) was smaller in LPs compared with BM ( P ≪ .05). For an examination of BM CD34+ cells before the mobilization chemotherapy, samples of 16 patients were available. The mean proportion of c-kit expressing CD34+ ceils in the bone marrow during G-CSF- stimulated reconstitution decreased 1.8-fold compared with baseline values. There was no difference in the proportion of BM-derived CD34+/Thy-1+ cells and CD34+/CD45RA+ cells between steady-state hematopoiesis and G-CSF-supported recovery. Our data suggest that during G-CSF-enhanced recovery, CD34+ cells in the PB are enriched with more primitive progenitor cells to evenly replenish the BM after the chemotherapy-related cytotoxic damage.